Floatz logo

Onalespib

Platinum-Resistant Fallopian Tube Carcinoma

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
89/ 100

Competitive context

73 Active assets in the Platinum-Resistant Fallopian Tube Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Women's Hospital School Of Medicine Zhejiang University
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 3BB
Cyclophosphamide
Mayo Clinic
Phase 2BB
Pembrolizumab
Roswell Park Cancer Institute
Phase 2BB
TAMOXIFEN
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3BB

View all 50 →

Same molecule, other indications

Onalespib is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
49 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →